Management of Anemia in Oncology Patients

Introduction to Transfusion Guidelines

• The European Society for Medical Oncology (ESMO) guidelines state that RBC transfusions are justified in patients with Hb < 7-8 g/dL and/or severe anemia-related symptoms, even at higher Hb levels 1, 3
• The National Comprehensive Cancer Network (NCCN) guidelines recommend transfusion to maintain hemoglobin 7-9 g/dL in asymptomatic, hemodynamically stable patients with chronic anemia 4

Transfusion Thresholds

• Transfusion is clearly indicated when hemoglobin falls below 7.5-8 g/dL, regardless of whether chemotherapy is planned 2, 3, 4
• At 7.6 g/dL, this patient meets the threshold for immediate transfusion based on multiple oncology guidelines 3, 4, 5

Chemotherapy Administration

• There is no contraindication to administering chemotherapy on the same day as transfusion once hemoglobin is corrected, except when using cardiotoxic chemotherapy agents 1, 5
• If using cardiotoxic chemotherapy agents, give IV iron either before or after (not on the same day as) the cardiotoxic chemotherapy, or at the end of the treatment cycle 1

Iron Deficiency Management

• Absolute iron deficiency is defined as ferritin < 100 ng/mL; these patients should receive IV iron 1
• Functional iron deficiency is defined as TSAT < 20% and ferritin > 100 ng/mL; these patients should also receive IV iron, especially if ESA therapy is considered 1, 4
• IV iron has superior efficacy compared to oral iron and should be the preferred route for supplementation 1, 4

Transfusion Administration

• Transfuse single units sequentially rather than multiple units simultaneously, reassessing after each unit 5
• Packed red blood cells must be crossmatched before transfusion to confirm ABO compatibility 5
• Monitor for transfusion reactions, volume overload, and signs of circulatory compromise during administration 5, 6

Risks and Pitfalls

• RBC transfusions carry significant risks including increased venous and arterial thromboembolism, mortality risk, febrile non-hemolytic reactions, congestive heart failure, circulatory overload, and potential for viral/bacterial transmission 3, 5
• Transfusion-related immunosuppression may increase infection risk 3
• In oncology surgery settings, RBC transfusions have been associated with increased risk of cancer recurrence 3